Balaji Venugopal
Apollo Hospitals · 123 works · 7,459 citations · h-index 25
Top works
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
- Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
- Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
- A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
- Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect
- Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
- Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer
- A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)
- Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.
- Real‐world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer
- Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
- Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma
- First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study